Evidence map›Paper›PMID 41226133›Full record

ArticleMolecules (Basel, Switzerland)2025

Identification of Marrubiin as a Cathepsin C Inhibitor for Treating Rheumatoid Arthritis.

Fei-Long Zhou, Yu Zhang, Cui Chang, Da-Xing Shi, Xing Chen, Xin-Hua Liu, Xiao-Bao Shen

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fei-Long ZhouMedical School, Fuyang Normal University, Fuyang 236037, China.
Yu ZhangInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
Cui ChangInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
Da-Xing ShiInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
Xing ChenInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
Xin-Hua LiuInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
Xiao-Bao ShenMedical School, Fuyang Normal University, Fuyang 236037, China.

Funding

Foundation of Fuyang Normal University 2021KYQD0027Foundation of Fuyang Normal University 2024FYNUFN12Foundation of Fuyang Normal University 2024xqhz051Hefei Technology College horizontal project 2024HXKT012Natural Science Foundation of Anhui Education Department 2022AH051331Natural Science Foundation of Anhui Education Department 2022AH051340
6 · The paper itself

Abstract

Cathepsin C (CTSC) mediates neutrophil serine protease (NSP) maturation, contributing to inflammatory cascades, making it a key therapeutic target. In this study, through large-scale screening of a natural product library, marrubiin, a diterpenoid lactone compound, was identified as a potent CTSC inhibitor, which holds potential value in the treatment of inflammatory diseases. It inhibited human recombinant CTSC (IC

Indexed as

Arthritis, RheumatoidCathepsin CDiterpenesAnimalsArthritis, ExperimentalDisease Models, AnimalHumansLipopolysaccharidesMaleMiceMolecular Docking SimulationNeutrophilsCathepsin CDiterpenesLipopolysaccharidesanti-inflammatoryarthritiscathepsin Cmarrubiinnatural product

Identifiers

PMID41226133
PMCPMC12610274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.